Liposarcoma – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of liposarcoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of liposarcoma for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s liposarcoma forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of liposarcoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 27 liposarcoma patient populations, including the following:
- Diagnosed incident cases of HNTE, retroperitoneum and abdomen & thoracic liposarcoma.
- Diagnosed incident cases of HNTE, retroperitoneum and abdomen & thoracic liposarcoma by stage and resection status.
- Diagnosed prevalent cases of HNTE, retroperitoneum and abdomen & thoracic liposarcoma.
- Diagnosed recurrent incident cases of unresectable HNTE, retroperitoneum and abdomen & thoracic liposarcoma.
- Diagnosed first-line drug-treatable population of HNTE, retroperitoneum and abdomen & thoracic liposarcoma.
Note: Coverage may vary by country.
